• NLRP10, Keratinocyte Survival, and Skin Barrier

  2026-10-05

  The 2024 Cell Death and Disease study identifies NLRP10 as a regulator of epidermal homeostasis, linking reduced NLRP10 expression in atopic dermatitis with impaired keratinocyte survival, differentiation, and barrier function. Its combination of human skin evidence, an air-lift human skin equivalent model, and mechanistic analysis supports NLRP10 as a biologically plausible therapeutic target, while leaving clinical efficacy and broader transferability unresolved.

• Glycogen Assays in Circadian Exercise Research

  2026-10-05

  A source-grounded overview of how glycogen measurement informs circadian exercise research, what a recent mouse study found about training time, and why colorimetric glycogen assays should be interpreted within clear biological and analytical limits.

• GM 6001 (Galardin): MMP Research Guide

  2026-10-04

  GM 6001, also called Galardin or ilomastat, is a broad-spectrum matrix metalloproteinase inhibitor used to study extracellular matrix remodeling and MMP-linked signaling. Reported effects span meniscal healing research, EGFR transactivation inhibition, cancer cell proliferation modulation, and vascular smooth muscle cell migration inhibition, but these findings are model-specific and do not establish clinical efficacy.

• Hyperglycemia, Pin1/BRD4, and Gastric Cancer

  2026-10-03

  Yu and colleagues report that a high-glucose environment promotes gastric carcinoma proliferation and migration through a Pin1/BRD4-associated regulatory axis. The study combines cellular perturbation with preclinical tumor-growth and metastasis models, linking hyperglycemia to G1/S progression, NAP1L1 and p21 regulation, and clinically relevant cancer phenotypes.

• ERAD Hijacking for Transmembrane Protein Degradation

  2026-10-02

  Song and colleagues introduce ERAD-engaging chimeras (ERADECs), a small-molecule targeted protein degradation platform that redirects endoplasmic reticulum-associated degradation toward transmembrane proteins. Desonide-based ERADECs produced SYVN1- and ERAD-dependent PD-L1 degradation with sub-nanomolar activity and stronger tumor suppression than a clinically used PD-L1 antibody in the reported models.

• Epalrestat B1743 for Reliable Cell Assays

  2026-10-01

  This scenario-driven guide explains how Epalrestat (SKU B1743) can support reproducible cell viability, proliferation, and cytotoxicity studies involving aldose reductase, oxidative stress, and polyol pathway biology. It covers formulation, controls, protocol planning, data interpretation, and practical product-selection criteria.

• Flubendazole Workflows for Autophagy Assays

  2026-10-01

  Build more informative autophagy experiments with Flubendazole by pairing pathway readouts with time-resolved measurements of growth inhibition and cell death. This workflow is especially useful for cancer biology research, while its limitations and transferability to neurodegenerative disease models are made explicit.

• NOXA–BCL-XL/MCL-1 Balance in Rhabdomyosarcoma

  2026-09-30

  A 2021 Neoplasia study combined drug screening with patient-derived rhabdomyosarcoma models to identify ABT-263/Navitoclax as a potent chemosensitizer. Its mechanistic analysis connects treatment response to the NOXA–BCL-XL/MCL-1 balance, highlighting mitochondrial apoptotic control as a potential route for re-sensitizing recurrent tumors.

• OCT Transport and Alizarin Exposure in Aedes aegypti

  2026-09-30

  Kennel and Rouhier examined how Aedes aegypti mosquitoes clear Olsalazine and two alizarin dyes while profiling six putative organic cation transporter genes. The study found that xenobiotic structure strongly affected excretion patterns and mortality, whereas transporter transcript profiles changed only modestly, establishing a useful foundation for future mosquito detoxification research.

• Lithium, Exosomal Wnt10a, and Bone Regeneration

  2026-09-29

  The reference study identifies a mechanistic route by which lithium enhances BMSC osteogenesis: MARK2-associated Rab11a/Rab11FIP1 trafficking increases exosomal Wnt10a secretion, activating Wnt/β-catenin signaling. Its comparison of lithium-conditioned exosomes and GelMA delivery provides a useful framework for engineering cell-free strategies for bone repair, while also highlighting translational questions concerning dosing, exosome heterogeneity, and model generalizability.

• Pseudo-UTP: A Strategic Path to Better mRNA

  2026-09-29

  Pseudo-UTP is more than a UTP substitute: it is a design variable that can influence RNA persistence, translation, innate immune recognition, and analytical interpretation. This thought-leadership guide connects pseudouridine chemistry with experimental validation and translational strategy for mRNA vaccines, gene therapy RNA modification, and broader RNA research.

• Capsazepine: Designing Better TRPV1 Assays

  2026-09-28

  Capsazepine is a TRPV1 ion channel antagonist that can sharpen mechanistic studies of nociception, sensory signaling, and apoptosis. This guide explains how to use its pharmacology alongside multidimensional pain assays without confusing direct TRPV1 effects with broader inflammatory or affective pathways.

• Bazedoxifene: Assays for IL-6/GP130 Research

  2026-09-28

  Bazedoxifene offers researchers a way to investigate both estrogen-receptor biology and the emerging IL-6/GP130 cancer-signaling hypothesis. This workflow separates those mechanisms, prioritizes target engagement before downstream readouts, and includes practical controls for interpreting cell-based results.

• Gemcitabine HCl: From Assay to MRI-Guided Tumors

  2026-09-27

  Pair Gemcitabine HCl’s DNA replication inhibition with cell-based response assays and longitudinal MRI to connect drug exposure to pancreatic tumor readouts. A four-animal imaging workflow can improve study throughput, while carefully staged controls help separate tumor response from assay and measurement variability.

• FITC-Concanavalin A (ConA) Conjugate Guide

  2026-09-26

  FITC-Concanavalin A (ConA) Conjugate provides a fluorescent readout for accessible α-D-glucose and α-D-mannose residues on cell-surface glycoproteins and glycolipids. It is intended for carbohydrate-focused immunofluorescence and flow cytometry workflows, not for detecting non-carbohydrate targets or as a general-purpose cell stain.

7940 records 1/530 page Next 12345 下5页 Last page